ESTRO 2024 - Abstract Book

S57

Invited Speaker

ESTRO 2024

Results

The SENOMAC trial enrolled 2766 patients in five countries between January 2015 and December 2021. The per protocol population consisted of 2540 patients, 1335 in the SLN biopsy only and 1205 in the cALND group. RT including nodal target volumes was given to 1192 (89.9%) and 1058 (88.4%) patients, respectively. Median follow-up was 3.9 years (0.1-7.9). Additional non-SLN metastases were found on cALND in 403 patients (34.5%). The final pathological nodal classification among 2485 patients having primary surgery was pN1 in 1311 (99.5%) patients in the SLN biopsy only group and 1016 (87.1%) patients in the cALND group, pN2 (4-9 metastases) in 7 (0.5%) patients in the SLN biopsy only and in 116 (9.9%) patients in the cALND group, and pN3 (≥10 metastases) in 35 (3.0%) patients in the cALND group. Overall, 191 recurrences or deaths were reported. Estimated five-year recurrence-free survival was 89.7% (95% CI 87.5%-91.9%) in the SLN biopsy only group and 88.7% (86.3%-91.1%) in the cALND group, with a hazard ratio of 0.89 (0.66-1.19), significantly (p<0.001) below the prespecified noninferiority margin of 1.44. For RT quality control, all 1360 patients randomized in Sweden or Denmark until May 31, 2019, were considered and 1154 RT plans evaluated. Reported eCRF data agreed with RT plan evaluation in 1146 (99.3%) and 1115 (96.6%), respectively, separately assessing RT to the breast or chest wall and to nodal target volumes in the per-protocol population.

Conclusions

In clinically node-negative breast cancer, SLN biopsy alone is non-inferior to cALND in patients with sentinel node macrometastases receiving nodal RT and adjuvant systemic therapy.

3373

Knowledge and experience transfer to improve research outcomes

Erica Bennett

Bon Secours, Radiotherapy, Cork, Ireland. UPMC, Hillman Cancer Centre, Ireland, Ireland

Abstract:

Background

Oncology research encompasses a broad range of academic, clinical, therapeutic, and diagnostic combinations and clinical trial management is often associated with disciplines other than Radiation Therapists (RTT). Opportunities for RTTs to be involved in cancer research may not be apparent and the career pathway is less well-defined unless an Advanced Practice Framework is already utilised.

Discussion

Knowledge and skills acquired during radiotherapy practice are transferrable to many healthcare developments and strategies and this presentation focuses on the value RTTs can bring to the multi-disciplinary research forum. Technical, and patient management expertise underpinned by regulatory compliance are essential skills required for